Non-viral chimeric antigen receptor (CAR)-T cells are gaining attention for their cancer-killing ability with reduced side effects. Traditional CAR-T cell engineering relies on lentivirus, which causes random chromosomal integration, permanent CAR expression, and adverse effects from persistent immunologic stimulation. To
With 1 person dying of cancer every 4 minutes, there is a need for more research. Explore our cancer research products to help change these statistics.
VivoVist™ is a revolutionary nanotechnology super contrast agent of alkaline earth metal nanoparticles for enhanced X-ray imaging in microCT.
Cervical cancer is the 4th most prevalent cancer among women, and the 7th most common cancer. MBLI provides HPV-related tetramers for use in research.
MBLI QuickSwitch™ kit technology aims to replicate the immune response by mimicking peptide exchange on an MHC molecule.
There is more data that highlights the significant role of m7G modification in human diseases, particularly cancer.
In vivo antibody studies offer a wide range of applications. Discover the significant impact of antibody selection on your experiment.
Researchers take advantage of MBL International’s recombinant IL-18 to activate varying cells like peripheral blood cells, macrophages, NK cells and T cells to identify targets.
Krishgen is the only manufacturer of ELISA for pharmacokinetic studies of BsAbs, with 40+ drug targets in a sensitive, highly specific ELISA format.
Chimeric Antigen Receptor (CAR) T cell therapy is a revolutionary approach in the field of cancer immunotherapy.